<DOC>
	<DOCNO>NCT00948168</DOCNO>
	<brief_summary>The purpose study determine type 2 diabetic patient secondary failure combine oral therapy whether , besides improvement glycemic control , addition exenatide , new drug introduce treat diabetes addition insulin current therapy , 6 month associate improvement beta-cell function , insulin sensitivity follow 24-hours discontinuation drug .</brief_summary>
	<brief_title>Effect Exenatide Glucose Homeostasis Determinants Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>type 2 diabetes subject 40 80 year body mass index ( BMI ) 25 40 kg/mÂ² baseline glycated haemoglobin ( HbA1c ) &gt; 7.0 % , despite maximallytolerated combined oral therapy BCF stimulant ( sulfonylurea repaglinide ) plus metformin previous current use glitazone previous use systemic glucocorticoid , weightreducing drug ( ) sibutramine previous exposure GLP1 receptor agonist DPP4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>T2DM</keyword>
	<keyword>exenatide</keyword>
	<keyword>HbA1c</keyword>
	<keyword>weight</keyword>
	<keyword>waist circumference</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>beta-cell function</keyword>
</DOC>